AGTC - アプライド・ジェネティック・テクノロジ―ズ (Applied Genetic Technologies Corporation)

AGTCのニュース

   Applied Genetic Technologies (NASDAQ:AGTC) Upgraded at Zacks Investment Research  2021/12/10 21:48:42 Dakota Financial News
Applied Genetic Technologies (NASDAQ:AGTC) was upgraded by Zacks Investment Research from a sell rating to a hold rating in a research note issued to investors on Friday, Zacks.com reports. According to Zacks, Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. It develops gene therapy products for inherited orphan ophthalmology diseases. Its lead product candidates []
   Brokerages Anticipate Applied Genetic Technologies Co. (NASDAQ:AGTC) to Post -$0.37 EPS  2021/12/05 20:44:41 Transcript Daily
Equities research analysts expect that Applied Genetic Technologies Co. (NASDAQ:AGTC) will post earnings per share of ($0.37) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Applied Genetic Technologies earnings, with the highest EPS estimate coming in at ($0.31) and the lowest estimate coming in at ($0.42). Applied Genetic Technologies []
   Should Applied Genetic Technologies Corporation (NASDAQ: AGTC) Revive After A -296.31% Drop From Highs?  2021/11/25 18:00:00 Marketing Sentinel
During the last session, Applied Genetic Technologies Corporation (NASDAQ:AGTC)s traded shares were 0.38 million, with the beta value of the company hitting 1.91. At the end of the trading day, the stocks price was $2.44, reflecting an intraday gain of 2.09% or $0.05. The 52-week high for the AGTC share is $9.67, that puts it Should Applied Genetic Technologies Corporation (NASDAQ: AGTC) Revive After A -296.31% Drop From Highs? Read More »
   AGTC Appoints Abraham Scaria, Ph.D., as Chief Science Officer  2021/11/16 13:00:00 Intrado Digital Media
GAINESVILLE, Fla., and CAMBRIDGE, Mass., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare inherited retinal diseases (IRDs), today announced the appointment of Abraham Scaria, Ph.D., as Chief Science Officer.
   FY2022 EPS Estimates for Applied Genetic Technologies Co. Decreased by Cantor Fitzgerald (NASDAQ:AGTC)  2021/11/15 08:32:41 Dakota Financial News
Applied Genetic Technologies Co. (NASDAQ:AGTC) Equities research analysts at Cantor Fitzgerald decreased their FY2022 EPS estimates for Applied Genetic Technologies in a research note issued on Wednesday, November 10th. Cantor Fitzgerald analyst K. Kluska now expects that the biotechnology company will post earnings per share of ($1.61) for the year, down from their prior []
   Applied Genetic Technologies Corp Shares Near 52-Week Low - Market Mover  2021/07/16 00:34:18 Kwhen Finance
Applied Genetic Technologies Corp (AGTC) shares closed today at 1.7% above its 52 week low of $3.53, giving the company a market cap of $153M. The stock is currently down 12.2% year-to-date, down 36.2% over the past 12 months, and down 76.3% over the past five years. This week, the Dow Jones Industrial Average rose 0.7%, and the S&P 500 rose 0.4%. Trading Activity Trading volume this week was 34.8% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.7. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -1471.3% The company's stock price performance over the past 12 months lags the peer average by -109.0% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Applied Genetic Technologies: Weak Early Clinical Ocular Results Highlight Increased Risk  2021/07/15 02:47:09 Seeking Alpha
   Applied Genetic Technologies Corp Shares Close in on 52-Week Low - Market Mover  2021/07/15 00:11:01 Kwhen Finance
Applied Genetic Technologies Corp (AGTC) shares closed today at 1.7% above its 52 week low of $3.53, giving the company a market cap of $159M. The stock is currently down 8.6% year-to-date, down 33.6% over the past 12 months, and down 75.9% over the past five years. This week, the Dow Jones Industrial Average rose 0.9%, and the S&P 500 rose 0.6%. Trading Activity Trading volume this week was 73.4% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.7. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -847.7% The company's stock price performance over the past 12 months lags the peer average by -107.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Huge Demand of Next Generation Contact Lenses and Visual Prostheses Market by 2026 | Abbott, Allergan, Bionic Sight, Alden Optical, Applied Genetic Technologies  2021/07/13 13:52:25 Tramways Monthly
Get Sample Report Buy Complete Report Request for Customization Global Next Generation Contact Lenses and Visual Prostheses Market has significant drivers and future opportunities for vendors, the study includes in-depth assessment of competitive environment, product market size, product benchmarking, market dynamics, product innovations, financial analysis, strategic analysis, etc. Apart from this, the report examines []
   Volume Actives: Electrameccanica Vehicles Corp. (NASDAQ:SOLO), Applied Genetic Technologies Corporation (NASDAQ:AGTC)  2021/07/07 22:05:45 Stock Equity
Electrameccanica Vehicles Corp. (NASDAQ:SOLO) with the stream of -3.20% also noticed, India Applied Genetic Technologies Corporation (NASDAQ:AGTC) encountered a rapid change of -1.30% in the last hour of Wednesdays trading The post Volume Actives: Electrameccanica Vehicles Corp. (NASDAQ:SOLO), Applied Genetic Technologies Corporation (NASDAQ:AGTC) appeared first on Stocks Equity .
   Otonomy's OTO-825 Gene Therapy Can Restore Meaningful Hearing Function, Animal Study Shows  2021/05/14 18:59:13 Benzinga
Otonomy Inc (NASDAQ: OTIC ) may have hit a snag with the development of its lead ear disorder candidate Otividex . Still, the company is trumpeting an early win for a gene therapy designed to treat congenital hearing loss. The drug candidate, dubbed OTO-825, reduced hearing loss and repaired structural damage in the inner ear in two mouse models of genetically driven hearing deficiency. Otonomy and its partner Applied Genetic … Full story available on Benzinga.com
   Concept Companies Breaks Ground on Expansion for AGTC in Alachua's Foundation Park  2021/05/14 16:54:00 Benzinga
GAINESVILLE, Fla. , May 14, 2021 /PRNewswire/ -- Concept Companies, a Gainesville headquartered full-service real estate development and construction firm, has executed an agreement to commence development of a new laboratory facility for Applied Genetic Technologies Corporation (NASDAQ: AGTC ). The location will include quality control labs and a manufacturing suite, expanding AGTCs existing footprint in Alachua, FL. The 21,000 square foot building is expected to be ready for occupancy in 2022. " Alachua is the perfect location for companies like AGTC who operate out of corporate offices in larger municipalities such as Cambridge, but desire to have more customized, flexible and affordable R&D and manufacturing facilities in our business-friendly Sunshine State ," said Brian … Full story available on Benzinga.com
   The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts  2021/05/14 11:59:10 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 13) Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN ) Novo Nordisk A/S (NYSE: NVO ) Vaccitech plc (NASDAQ: VACC ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows May 13) 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT ) ADC Therapeutics SA (NYSE: ADCT ) Accelerate Diagnostics, Inc. (NASDAQ: AXDX ) Achilles Therapeutics plc (NASDAQ: ACHL ) Akouos, Inc. (NASDAQ: AKUS ) (announced its first-quarter results) Applied Genetic Technologies Corporation (NASDAQ: AGTC ) Aprea Therapeutics, Inc. (NASDAQ: APRE ) Aquestive Therapeutics, Inc. (NASDAQ: AQST ) Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT ) Atea Pharmaceuticals, Inc. (NASDAQ: AVIR ) Atreca, Inc. (NASDAQ: BCEL ) Bellerophon Therapeutics, Inc. (NASDAQ: BLPH ) Biomea Fusion, Inc. (NASDAQ: BMEA ) Capricor Therapeutics, Inc. (NASDAQ: CAPR ) Cellectis S.A. (NASDAQ: CLLS ) ContraFect Corporation (NASDAQ: CFRX ) Co-Diagnostics, Inc.
   The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts  2021/05/14 11:59:10 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 13) Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN ) Novo Nordisk A/S (NYSE: NVO ) Vaccitech plc (NASDAQ: VACC ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows May 13) 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT ) ADC Therapeutics SA (NYSE: ADCT ) Accelerate Diagnostics, Inc. (NASDAQ: AXDX ) Achilles Therapeutics plc (NASDAQ: ACHL ) Akouos, Inc. (NASDAQ: AKUS ) (announced its first-quarter results) Applied Genetic Technologies Corporation (NASDAQ: AGTC ) Aprea Therapeutics, Inc. (NASDAQ: APRE ) Aquestive Therapeutics, Inc. (NASDAQ: AQST ) Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT ) Atea Pharmaceuticals, Inc. (NASDAQ: AVIR ) Atreca, Inc. (NASDAQ: BCEL ) Bellerophon Therapeutics, Inc. (NASDAQ: BLPH ) Biomea Fusion, Inc. (NASDAQ: BMEA ) Capricor Therapeutics, Inc. (NASDAQ: CAPR ) Cellectis S.A. (NASDAQ: CLLS ) ContraFect Corporation (NASDAQ: CFRX ) Co-Diagnostics, Inc.
   Applied Genetic's XLRP Gene Therapy Shows Improved, Durable Response In Retinal Sensitivity  2021/05/06 13:04:04 Benzinga
Applied Genetic Technologies Corporation (NASDAQ: AGTC ) has announced additional data from the ongoing X-linked retinitis pigmentosa (XLRP) gene therapy Phase 1/2 trial, including 12-month data from Groups 5 & 6 and 24-month data from two of three Group 4 patients. Groups 5 and 6 had a 50% response rate among patients who met the inclusion criteria for the Skyline and Vista trials. Consistent with previously reported 6-month data from Groups 2, 4, 5, and 6, … Full story available on Benzinga.com

calendar